India's biotech and biomaterials gain EU plaudits:
This article was originally published in Clinica
India's biotechnology and biomaterials sectors are among those most suited to co-operation between the EU and India, "given the state-of-the-art of science" in the two regions, suggests a European Commission background paper. Though known as the "third world research superpower", India is still underdeveloped, it says. Despite this, the country's biomaterial sciences are featured for their "high-level of expertise", while the National Institute of Immunology and the International Centre for Genetic Engineering and Biotechnology are described as world class institutions. Biotechnology is not currently a priority of its E2.5 billion ($2.2 billion, 0.72% of GDP) R&D budget, 17% of which is provided by industry.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.